Research Paper Volume 15, Issue 11 pp 5032—5051
CLDN5 identified as a biomarker for metastasis and immune infiltration in gastric cancer via pan-cancer analysis
Figure 4. The relationship between CLDN5 expression and cancer patients' DSS. (A) A forest plot of CLDN5 hazard ratios in 33 multiple cancers. (B) Kaplan-Meier survival curves of DSS for patients groups defined by CLDN5 expression in GBM, KIRP, COAD, STAD, LUSC, LIHC, UVM, PAAD, and KIRC.